Literature DB >> 10636469

PhosphoCREB and CREM/ICER: positive and negative regulation of proenkephalin gene expression in the paraventricular nucleus of the hypothalamus.

D Borsook1, O Smirnova, O Behar, S Lewis, L A Kobierski.   

Abstract

In the hypothalamic paraventricular nucleus (PVN), the proenkephalin gene may be upregulated by lipopolysaccharide (LPS) and downregulated by the GABA-A agonist muscimol. Candidate transcription factors regulating the proenkephalin gene in opposite directions are cAMP-response-element-binding protein (CREB) (when phosphorylated, a positive regulator) and cAMP-responsive modulatory inducible cAMP early repressor (CREM/ICER) (a negative regulator). Our results demonstrate that CREM alpha,beta,gamma transcripts and ICER are induced in the PVN by LPS and remain elevated for periods of up to 12 h. PhosphoCREB is elevated after LPS administration, peaking at 8 h, but remaining elevated over control levels at 12 h. Phospho-CREB induction by LPS is also seen in primary hypothalamic cultures. Cotransfection of ICER with ENK-CAT12 into primary hypothalamic cultures produced a decrease in chloramphenicol acetyl transferase (CAT) levels following cAMP or LPS stimulation. PhosphoCREB is downregulated and CREM/ICER is upregulated in the PVN by muscimol, suggesting that the regulation of these transcription factors may underlie the inhibitory effect of muscimol on target genes in the PVN.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10636469     DOI: 10.1385/JMN:12:1:35

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  62 in total

1.  Isolation of RNA.

Authors:  S L Berger; J M Chirgwin
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

Review 2.  Coupling signalling pathways to transcriptional control: nuclear factors responsive to cAMP.

Authors:  K T Tamai; L Monaco; F Nantel; E Zazopoulos; P Sassone-Corsi
Journal:  Recent Prog Horm Res       Date:  1997

3.  Proenkephalin gene regulation in the paraventricular nucleus by GABA: interactions with opioid systems in a transgenic model.

Authors:  D Borsook; O Falkowski; O Smirnova
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

4.  Expression of inducible cAMP early repressor (ICER) in hypothalamic magnocellular neurons.

Authors:  S M Luckman; H J Cox
Journal:  Brain Res Mol Brain Res       Date:  1995-12-28

5.  Glucocorticoids inhibit stress-induced phosphorylation of CREB in corticotropin-releasing hormone neurons of the hypothalamic paraventricular nucleus.

Authors:  G Légrádi; D Holzer; L P Kapcala; R M Lechan
Journal:  Neuroendocrinology       Date:  1997-08       Impact factor: 4.914

6.  Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice.

Authors:  E Hirsch; V M Irikura; S M Paul; D Hirsh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  Electroconvulsive seizure increases the expression of CREM (cyclic AMP response element modulator) and ICER (inducible cyclic AMP early repressor) in rat brain.

Authors:  L R Fitzgerald; V A Vaidya; R Z Terwilliger; R S Duman
Journal:  J Neurochem       Date:  1996-01       Impact factor: 5.372

8.  Activating transcription factor-3 stimulates 3',5'-cyclic adenosine monophosphate-dependent gene expression.

Authors:  H M Chu; Y Tan; L A Kobierski; L B Balsam; M J Comb
Journal:  Mol Endocrinol       Date:  1994-01

Review 9.  Nuclear response to cyclic AMP: central role of transcription factor CREM (cyclic-AMP-responsive-element modulator).

Authors:  E Lalli; J S Lee; D Masquilier; F Schlotter; N S Foulkes; C A Molina; P Sassone-Corsi
Journal:  Biochem Soc Trans       Date:  1993-11       Impact factor: 5.407

Review 10.  CREM: a master-switch in the transcriptional response to cAMP.

Authors:  M Lamas; L Monaco; E Zazopoulos; E Lalli; K Tamai; L Penna; C Mazzucchelli; F Nantel; N S Foulkes; P Sassone-Corsi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1996-04-29       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.